BD’s Diabetes Division Is Unruffled By Continuous Monitoring, Inhaled Insulin
This article was originally published in The Gray Sheet
Executive Summary
BD remains confident in its traditional needle-and-test-strip-based diabetes management business despite the advent of continuous glucose monitoring and inhaled insulin delivery - technologies touted as less invasive, more user-friendly alternatives